These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 9635530)

  • 21. Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion.
    Okumura Y; Yamamoto Y; Zhang Z; Toyama T; Kawasoe T; Ibusuki M; Honda Y; Iyama K; Yamashita H; Iwase H
    BMC Cancer; 2008 Oct; 8():287. PubMed ID: 18837981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apoptosis in breast carcinoma.
    González-Cámpora R; Galera Ruiz MR; Vázquez Ramírez F; Ríos Martín JJ; Fernández Santos JM; Ramos Martos MM; Gómez Pascual A
    Pathol Res Pract; 2000; 196(3):167-74. PubMed ID: 10729921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast.
    Rudas M; Neumayer R; Gnant MF; Mittelböck M; Jakesz R; Reiner A
    Eur J Cancer; 1997 Jan; 33(1):39-44. PubMed ID: 9071897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
    Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S
    Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.
    Brower ST; Ahmed S; Tartter PI; Bleiweiss I; Amberson JB
    Ann Surg Oncol; 1995 Sep; 2(5):440-4. PubMed ID: 7496840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinic-Pathological Features of Breast Ductal Carcinoma
    Zheng J; Zhou T; Li F; Shi J; Zhang L
    Cancer Invest; 2020 Feb; 38(2):113-121. PubMed ID: 31939679
    [No Abstract]   [Full Text] [Related]  

  • 29. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
    Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
    Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.
    Leal CB; Schmitt FC; Bento MJ; Maia NC; Lopes CS
    Cancer; 1995 Apr; 75(8):2123-31. PubMed ID: 7697603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
    Quinn CM; Ostrowski JL; Harkins L; Rice AJ; Loney DP
    Histopathology; 1998 Dec; 33(6):531-6. PubMed ID: 9870147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas.
    Zhang GJ; Kimijima I; Abe R; Kanno M; Katagata N; Hara K; Watanabe T; Tsuchiya A
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2329-35. PubMed ID: 9815631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic predisposition to ductal carcinoma in situ of the breast.
    Petridis C; Brook MN; Shah V; Kohut K; Gorman P; Caneppele M; Levi D; Papouli E; Orr N; Cox A; Cross SS; Dos-Santos-Silva I; Peto J; Swerdlow A; Schoemaker MJ; Bolla MK; Wang Q; Dennis J; Michailidou K; Benitez J; González-Neira A; Tessier DC; Vincent D; Li J; Figueroa J; Kristensen V; Borresen-Dale AL; Soucy P; Simard J; Milne RL; Giles GG; Margolin S; Lindblom A; Brüning T; Brauch H; Southey MC; Hopper JL; Dörk T; Bogdanova NV; Kabisch M; Hamann U; Schmutzler RK; Meindl A; Brenner H; Arndt V; Winqvist R; Pylkäs K; Fasching PA; Beckmann MW; Lubinski J; Jakubowska A; Mulligan AM; Andrulis IL; Tollenaar RA; Devilee P; Le Marchand L; Haiman CA; Mannermaa A; Kosma VM; Radice P; Peterlongo P; Marme F; Burwinkel B; van Deurzen CH; Hollestelle A; Miller N; Kerin MJ; Lambrechts D; Floris G; Wesseling J; Flyger H; Bojesen SE; Yao S; Ambrosone CB; Chenevix-Trench G; Truong T; Guénel P; Rudolph A; Chang-Claude J; Nevanlinna H; Blomqvist C; Czene K; Brand JS; Olson JE; Couch FJ; Dunning AM; Hall P; Easton DF; Pharoah PD; Pinder SE; Schmidt MK; Tomlinson I; Roylance R; García-Closas M; Sawyer EJ
    Breast Cancer Res; 2016 Feb; 18(1):22. PubMed ID: 26884359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apoptosis and cell proliferation in medullary carcinoma of the breast: a comparative study between medullary and non-medullary carcinoma using the TUNEL method and immunohistochemistry.
    Kajiwara M; Toyoshima S; Yao T; Tanaka M; Tsuneyoshi M
    J Surg Oncol; 1999 Apr; 70(4):209-16. PubMed ID: 10219015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation.
    Oka K; Suzuki T; Onodera Y; Miki Y; Takagi K; Nagasaki S; Akahira J; Ishida T; Watanabe M; Hirakawa H; Ohuchi N; Sasano H
    Int J Cancer; 2011 Apr; 128(8):1770-82. PubMed ID: 20533549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution of Hsp-27 and HER-2/neu in in situ and invasive ductal breast carcinomas.
    Storm FK; Gilchrist KW; Warner TF; Mahvi DM
    Ann Surg Oncol; 1995 Jan; 2(1):43-8. PubMed ID: 7530588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of astrocyte elevated gene-1, basic-fibroblast growth factor, beta-catenin, Ki-67, tumor necrosis factor-alfa with prognostic parameters in ductal carcinomas and ductal intraepithelial neoplasms.
    Erdem H; Gundogdu B; Ankarali H; Yasar M; Sener E; Oktay M; Bahadir A; Uzunlar AK; Gursan N; Ozaydin I; Sahiner C
    Niger J Clin Pract; 2015; 18(5):638-43. PubMed ID: 26096243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.